Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| future policies on use of blood products from COVID-19-positive donors | Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Document delays and frequencies of inadequate blood products for emergent cases | Other | The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals |
| Measure | Description | Time Frame |
|---|---|---|
| Time frame | Dates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted | 1 year |
Not provided
Not provided
Inclusion Criteria:
>_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)
Exclusion Criteria:
<18 years of age Prisoners Pregnant women
Not provided
Not provided
Not provided
COVID-19 patients typically present with fever, nonproductive cough, dyspnea, myalgia, and/or fatigue. The main cause of death in COVID-19 patients is acute respiratory distress syndrome(ARDS). ARDS is caused by a cytokine storm that triggers an attack on the body by pro-inflammatory cytokines and chemokines, eventually resulting in multiple organ failure and death.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jennifer Burris, Pharm D | Methodist Health System | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Methodist Dallas Medical Center- Clinical Research Institute | Dallas | Texas | 75203 | United States |
The investigator will make all possible efforts to ensure compliance with all policies regarding sharing of Protected Health Information(PHI) or research information. Only de-identified PHI will be shared in relevant research mediums. The data will be presented at local, regional, national, and international sites. The research gathered will be analyzed and submitted to relevant peer-reviewed medical journals for publication to add to the body of knowledge in the science community. All institutional identifiers will be removed prior to presentation.
Not mentioned in protocol
Not mentioned in protocol
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |